Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.66 |
| ▸ | FBP1 | P09467 | 2/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005734 | 1.00 | PTGS2 (0.78) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL10728549 | 0.93 | APP (0.70) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL10728554 | 0.93 | APP (0.70) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL9785831 | 0.91 | NFE2L2 (0.83) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL9785833 | 0.91 | NFE2L2 (0.83) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL14880486 | 0.89 | PTGS2 (0.63) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL20328414 | 0.88 | APP (0.70) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL492221 | 0.88 | APP (0.70) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL20328415 | 0.88 | APP (0.70) | PTGS2PTGS1NFE2L2MAOAMAOB | |
| SCHEMBL4733440 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1NFE2L2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021074275-A1 | EFFECTIVE PHOTOMODULATION OF LANTHANIDE (III) ION LUMINESCENCE IN THE VISIBLE OR NEAR-INFRARED RANGE | UNIVERSITE DE RENNES 1 (FR) | 2021-04-22 | — | — | WO | disclosed |
| US-9868873-B2 | Photochromic security enabled ink for digital offset printing applications | XEROX CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-9831417-B2 | Poling treatment method, magnetic field poling device, and piezoelectric film | YOUTEC CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9575246-B2 | Prepolymer, curable material, coating composition, non-linear optical material, optical waveguide and light control device | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2889684-A1 | PREPOLYMER, CURABLE MATERIAL, COATING COMPOSITION, NON-LINEAR OPTICAL MATERIAL, OPTICAL WAVEGUIDE AND LIGHT CONTROL DEVICE | Asahi Glass Company, Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20150153509-A1 | PREPOLYMER, CURABLE MATERIAL, COATING COMPOSITION, NON-LINEAR OPTICAL MATERIAL, OPTICAL WAVEGUIDE AND LIGHT CONTROL DEVICE | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20140319405-A1 | POLING TREATMENT METHOD, MAGNETIC FIELD POLING DEVICE, AND PIEZOELECTRIC FILM | KRYSTAL INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140191618-A1 | POLING TREATMENT METHOD, PLASMA POLING DEVICE, PIEZOELECTRIC BODY AND MANUFACTURING METHOD THEREOF, FILM FORMING DEVICE AND ETCHING DEVICE, AND LAMP ANNEALING DEVICE | YOUTEC CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20130305947-A1 | PHOTOCHROMIC SECURITY ENABLED INK FOR DIGITAL OFFSET PRINTING APPLICATIONS | XEROX CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-5015417-A | Electrooptical apparatus, liquid crystals, modulators | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| WO-1991003458-A1 | NONLINEAR OPTICAL DEVICE FROM 3-METHYL-4-METHOXY-4'-NITROSTILBENE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
| US-4985179-A | VINYLIDENE CYANIDE COPOLYMER, ORGANIC CRYSTAL | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4985178-A | Nonlinear optical device from 3-methyl-4-methoxy-4'-nitrostilbene | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4966730-A | CAPABILITY OF SECOND HARMONIC GENERATION USING ELECTROOPTICAL MODULAR | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-30 | — | — | US | disclosed |
| US-4961631-A | Nonlinear optical devices from derivatives of stilbene | E. I DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| US-4909964-A | With optical light source and means to direct radiation | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0344735-A2 | Non-linear optical material | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4004573-A | Process and apparatus for solar energy collection and retrieval | BATTELLE DEVELOPMENT CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
| US-4004572-A | Solar energy collection and retrieval employing reversible photochemical isomerization | BATTELLE DEVELOPMENT CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | PTGS2 4627/4885PTGS1 4668/4885NFE2L2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.